TEVA's stock rose 3-4% today, so some people think it is interesting. We can see from the most recent balance sheet that Teva Pharmaceutical Industries had liabilities of US$11.4b falling due within a year, and liabilities of US$23.2b due beyond that. Offsetting these obligations, it had cash of US$2.25b as well as receivables valued at US$3.39b due within 12 months. So it has liabilities totaling US$28.9b more than its cash and near-term receivables, combined.
The graph shows that TEVA gradually is paying back its debt and reducing the total amount of debt. It looks encouraging. Let's sleep on it.
No comments:
Post a Comment